FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049202207> ?p ?o ?g. }

• W2049202207 endingPage "1306" @default.
• W2049202207 startingPage "1302" @default.
• W2049202207 abstract "Therapeutic options for locally advanced pancreatic cancer (LAPC) include concurrent chemoradiation, induction chemotherapy followed by chemoradiation or systemic therapy alone. The original Gastro‑Intestinal Study Group and Eastern Cooperative Oncology Group studies defined fluorouracil (5‑FU) with concurrent radiation therapy followed by maintenance 5‑FU until progression, as the standard therapy for this subset of patients. Although this combined therapy has been demonstrated to increase local control and median survival from 8 to 12 months, almost all patients succumb to the disease secondary to either local or distant recurrence. Our earlier studies provided a strong rationale for the use of capecitabine in combination with concurrent radiation followed by maintenance capecitabine therapy. To report our clinical experience, we retrospectively evaluated our patients who were treated with maintenance capecitabine. We reviewed the medical records of patients with LAPC who received treatment with capecitabine and radiation, followed by a 4‑week rest, then capecitabine alone 1,000 mg twice daily (ECOG performance status 2 or age >70 years) or 1,500 mg twice daily for 14 days every 3 weeks until progressive disease. We treated 43 patients between September 2004 and September 2012. The population consisted of 16 females and 25 males, with a median age of 64 years (range, 38‑80 years). Patients received maintenance capecitabine for median duration of 9 months (range, 3‑18 months). The median overall survival (OS) for these patients was 17 months, with two patients still living and receiving therapy. The 6‑month survival rate was 91% (39/43), 1‑year survival rate was 72% (31/43) and 2‑year OS rate was 26% (11/43). Grade 3 or 4 toxicity was observed rarely: Hand‑foot syndrome (HFS) in two patients, diarrhea in one patient and peripheral neuropathy in one patient, and there was no mortality directly related to treatment. Capecitabine maintenance therapy following chemoradiation in LAPC offers an effective, tolerable and convenient alternative to 5‑FU. To the best of our knowledge, this is the largest study of its kind which has determined the safety and efficacy of capecitabine maintenance therapy for patients with LAPC." @default.
• W2049202207 created "2016-06-24" @default.
• W2049202207 creator A5014298745 @default.
• W2049202207 creator A5020029602 @default.
• W2049202207 creator A5044012618 @default.
• W2049202207 creator A5049509860 @default.
• W2049202207 creator A5055641905 @default.
• W2049202207 creator A5070561439 @default.
• W2049202207 date "2014-06-11" @default.
• W2049202207 modified "2023-09-30" @default.
• W2049202207 title "Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma" @default.
• W2049202207 cites W1565111474 @default.
• W2049202207 cites W1605038561 @default.
• W2049202207 cites W1763850369 @default.
• W2049202207 cites W1894182878 @default.
• W2049202207 cites W1910716144 @default.
• W2049202207 cites W1931508686 @default.
• W2049202207 cites W1968308685 @default.
• W2049202207 cites W1972373303 @default.
• W2049202207 cites W1995742535 @default.
• W2049202207 cites W2012142573 @default.
• W2049202207 cites W2015305721 @default.
• W2049202207 cites W2016236483 @default.
• W2049202207 cites W2017416278 @default.
• W2049202207 cites W2043287087 @default.
• W2049202207 cites W2044970916 @default.
• W2049202207 cites W2051063422 @default.
• W2049202207 cites W2061105596 @default.
• W2049202207 cites W2062080734 @default.
• W2049202207 cites W2075549113 @default.
• W2049202207 cites W2082601343 @default.
• W2049202207 cites W2106633271 @default.
• W2049202207 cites W2109713544 @default.
• W2049202207 cites W2124238648 @default.
• W2049202207 cites W2126532376 @default.
• W2049202207 cites W2128259734 @default.
• W2049202207 cites W2129725144 @default.
• W2049202207 cites W2138926750 @default.
• W2049202207 cites W2139248078 @default.
• W2049202207 cites W2140626944 @default.
• W2049202207 cites W2144690940 @default.
• W2049202207 cites W2150046939 @default.
• W2049202207 cites W2346018625 @default.
• W2049202207 cites W2530278026 @default.
• W2049202207 cites W81945182 @default.
• W2049202207 doi "https://doi.org/10.3892/ol.2014.2238" @default.
• W2049202207 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4114599" @default.
• W2049202207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25120712" @default.
• W2049202207 hasPublicationYear "2014" @default.
• W2049202207 type Work @default.
• W2049202207 sameAs 2049202207 @default.
• W2049202207 citedByCount "5" @default.
• W2049202207 countsByYear W20492022072015 @default.
• W2049202207 countsByYear W20492022072019 @default.
• W2049202207 countsByYear W20492022072020 @default.
• W2049202207 countsByYear W20492022072022 @default.
• W2049202207 crossrefType "journal-article" @default.
• W2049202207 hasAuthorship W2049202207A5014298745 @default.
• W2049202207 hasAuthorship W2049202207A5020029602 @default.
• W2049202207 hasAuthorship W2049202207A5044012618 @default.
• W2049202207 hasAuthorship W2049202207A5049509860 @default.
• W2049202207 hasAuthorship W2049202207A5055641905 @default.
• W2049202207 hasAuthorship W2049202207A5070561439 @default.
• W2049202207 hasBestOaLocation W20492022071 @default.
• W2049202207 hasConcept C121608353 @default.
• W2049202207 hasConcept C126322002 @default.
• W2049202207 hasConcept C141071460 @default.
• W2049202207 hasConcept C143998085 @default.
• W2049202207 hasConcept C2777909004 @default.
• W2049202207 hasConcept C2780210213 @default.
• W2049202207 hasConcept C2908647359 @default.
• W2049202207 hasConcept C509974204 @default.
• W2049202207 hasConcept C526805850 @default.
• W2049202207 hasConcept C71924100 @default.
• W2049202207 hasConcept C99454951 @default.
• W2049202207 hasConceptScore W2049202207C121608353 @default.
• W2049202207 hasConceptScore W2049202207C126322002 @default.
• W2049202207 hasConceptScore W2049202207C141071460 @default.
• W2049202207 hasConceptScore W2049202207C143998085 @default.
• W2049202207 hasConceptScore W2049202207C2777909004 @default.
• W2049202207 hasConceptScore W2049202207C2780210213 @default.
• W2049202207 hasConceptScore W2049202207C2908647359 @default.
• W2049202207 hasConceptScore W2049202207C509974204 @default.
• W2049202207 hasConceptScore W2049202207C526805850 @default.
• W2049202207 hasConceptScore W2049202207C71924100 @default.
• W2049202207 hasConceptScore W2049202207C99454951 @default.
• W2049202207 hasIssue "3" @default.
• W2049202207 hasLocation W20492022071 @default.
• W2049202207 hasLocation W20492022072 @default.
• W2049202207 hasLocation W20492022073 @default.
• W2049202207 hasLocation W20492022074 @default.
• W2049202207 hasOpenAccess W2049202207 @default.
• W2049202207 hasPrimaryLocation W20492022071 @default.
• W2049202207 hasRelatedWork W1988326884 @default.
• W2049202207 hasRelatedWork W2007621813 @default.
• W2049202207 hasRelatedWork W2027592937 @default.
• W2049202207 hasRelatedWork W2036431530 @default.
• W2049202207 hasRelatedWork W2036821810 @default.

• next